TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33783365

Group type: EXPERIMENTAL
Intervention: WeChat group chat-based BG management
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard clinical prenatal care
Number of subjects: 309
Study: 36137921

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Repeated measures of MVPA and ST
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 446
Study: 34186503

Group type: EXPERIMENTAL
Intervention: Web-based behavioral intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (written information about endocrine disruptors)
Number of subjects: 51
Study: 32815077

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention focused on maternal diet and physical activity
Number of subjects: 114
Study: 34349116

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Treatment type and anxiety symptoms
Number of subjects: 1008

Group type: COMPARATOR
Intervention: FIBSER scale assessment
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Assessment at 8 weeks
Number of subjects: 1008
Study: 35322469

Group type: EXPERIMENTAL
Intervention: Multidisciplinary family programme
Number of subjects: 62
Study: 32465171

Group type: EXPERIMENTAL
Intervention: ReDS-guided strategy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care strategy
Number of subjects: 250
Study: 34645287

Group type: EXPERIMENTAL
Intervention: Endovascular treatment plus usual care
Number of subjects: 0
Study: 34523948

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD) for 12 weeks, ad libitum energy intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Diet (ND)
Number of subjects: 0
Study: 35488195

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study: 34472698

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparators (placebo, sitagliptin 100 mg, liraglutide 1.8 mg)
Number of subjects: 0
Study: 36087843

Group type: EXPERIMENTAL
Intervention: TeaM OUT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 0
Study: 33908629

Group type: EXPERIMENTAL
Intervention: High-glycemic index meal (HGI; GI: 100)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-glycemic index meal (LGI; GI: 19)
Number of subjects: 18
Study: 34157132

Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 150 mg
Number of subjects: 955
Study: 35717531

Group type: EXPERIMENTAL
Intervention: Video training group
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-video group
Number of subjects: 18
Study: 32794582

Group type: EXPERIMENTAL
Intervention: D/L‐3‐hydroxybutyrate (hyperketotic condition)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 6
Study: 32825814

Group type: EXPERIMENTAL
Intervention: Tourniquet system using an elastic cuff and LOP (Group E)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Tourniquet system using a conventional cuff and LOP (Group C)
Number of subjects: 98
Study: 36232162

Group type: EXPERIMENTAL
Intervention: Multiple linear regression equations for aerobic exercise intensities at 50%, 60%, 70%, and 80%.
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Multiple linear regression equations for aerobic exercise intensities.
Number of subjects: 228
Study: 32623005

Group type: EXPERIMENTAL
Intervention: $10 loss-framed incentive to complete risk assessment and $25 unconditional incentive for colonoscopy completion
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Control group with risk assessment and direct access colonoscopy scheduling
Number of subjects: 1977
Study: 32859118

Group type: EXPERIMENTAL
Intervention: DAGIS intervention (multicomponent, preschool-based, family-involving)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 802
Study: 34236123

Group type: EXPERIMENTAL
Intervention: Concentric (resistance) biofeedback training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Isometric (non-resistance) biofeedback training
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 32599497

Group type: EXPERIMENTAL
Intervention: Low Dose Protocol (LDP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional Dose Protocol (CDP)
Number of subjects: 103
Study: 35720033

Group type: EXPERIMENTAL
Intervention: Gubitong Recipe (GBT)
Number of subjects: 0
Study: 33709856

Group type: EXPERIMENTAL
Intervention: Inhaled Glycopyrronium Bromide 6.25 µg BID
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Inhaled Glycopyrronium Bromide 12.5 µg BID
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Inhaled Glycopyrronium Bromide 25 µg BID
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Inhaled Glycopyrronium Bromide 50 µg BID
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Open-label tiotropium 18 µg once daily
Number of subjects: 733
Study: 32897319

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (abbreviated to four weekly 90‐minute sessions)
Number of subjects: 23
Study: 33300990

Group type: EXPERIMENTAL
Intervention: Sucrose (75 g in 300 mL drink)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Glucose (75 g in 300 mL drink)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sucrose vs Glucose
Number of subjects: 69
Study: 32493462

Group type: EXPERIMENTAL
Intervention: Active tDCS sessions over the left dorsolateral prefrontal cortex and right motor cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two sequences of two daily tDCS sessions over 5 days (one active and one sham)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 0
Study: 34667819

Group type: EXPERIMENTAL
Intervention: Webinar training
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Group discussion training
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 34293489

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG only
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgM only
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG and IgM
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Overall seroprevalence
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Seroprevalence by LGA
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Bayesian Adjustments
Number of subjects: 3142
Study: 32481557

Group type: EXPERIMENTAL
Intervention: Biscuit with a beverage of powdered mulberry leaves
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Biscuit with a beverage of powdered barley leaves
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Biscuit
Number of subjects: 18

Group type: COMPARATOR
Intervention: No biscuits
Number of subjects: 18
Study: 35653934

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT; N = 86)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nonspecific education/support (EDU; N = 44)
Number of subjects: 130
Study: 34124928

Group type: EXPERIMENTAL
Intervention: ACTV
Number of subjects: 725

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 725
Study: 33693863

Group type: EXPERIMENTAL
Intervention: CGRP-targeted monoclonal antibodies (CGRP-targeted mAbs) as add-on therapy to onabotulinumtoxinA
Number of subjects: 153

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 153
Study: 34905302

Group type: EXPERIMENTAL
Intervention: ER-tacrolimus
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: LCP-tacrolimus
Number of subjects: 92

Group type: COMPARATOR
Intervention: IR-tacrolimus
Number of subjects: 92
Study: 32881699

Group type: EXPERIMENTAL
Intervention: Visibility graph features derived from heart rate variability (HRV) data
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Traditional HRV features
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (infants who did not receive antibiotics)
Number of subjects: 49
Study: 34176862

Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement (AVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful observation
Number of subjects: 0
Study: 34189447

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg twice daily for 14 days
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 158
Study: 34743554

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg daily)
Number of subjects: 3112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3112
Study: 33670535

Group type: EXPERIMENTAL
Intervention: Muscle loss phenotype in patients >65 years old with cirrhosis
Number of subjects: 29018

Group type: EXPERIMENTAL
Intervention: Muscle loss phenotype in patients ≤50 years old with cirrhosis
Number of subjects: 29018

Group type: COMPARATOR
Intervention: Muscle loss phenotype in both GMP and inpatients with cirrhosis aged 51–65 years and >65 years
Number of subjects: 29018

Group type: EXPERIMENTAL
Intervention: Non-home discharges (nursing, skilled, long-term care) in patients with cirrhosis with muscle loss phenotype
Number of subjects: 29018
Study: 33298105

Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-fat (HCLF) diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-carbohydrate, high-fat (LCHF) diet
Number of subjects: 8
Study: 34088237

Group type: EXPERIMENTAL
Intervention: Intimate partner violence training program based on the theory of planned behavior
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 99
Study: 32170355

Group type: EXPERIMENTAL
Intervention: Topical co-delivery of platelet rich fibrin (PRF) and tranexamic acid (TA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (combined intravenous and topical TA)
Number of subjects: 80
Study: 36329307

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target < 130 mm Hg)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard blood pressure management (target < 180 mm Hg)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard blood pressure management
Number of subjects: 600
Study: 32462642

Group type: EXPERIMENTAL
Intervention: TKA design with baseplates size 3 or smaller
Number of subjects: 14966

Group type: EXPERIMENTAL
Intervention: TKA design with polyethylene insert thickness of 13 mm or larger
Number of subjects: 14966

Group type: EXPERIMENTAL
Intervention: Intraoperative tibia fractures treatment
Number of subjects: 14966

Group type: COMPARATOR
Intervention: Control group of 75 patients (80 knees)
Number of subjects: 14966
Study: 32160368

Group type: EXPERIMENTAL
Intervention: Topical dimethyl sulfoxide (DMSO) 50% solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tretinoin 0.5% cream
Number of subjects: 18
Study: 36186784

Group type: EXPERIMENTAL
Intervention: High-dose intravenous injection of vitamin C (200 mg/kg/24 h) for 4 days
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo (saline) for 4 days
Number of subjects: 620
Study: 32041717

Group type: EXPERIMENTAL
Intervention: Nacubactam 50 to 8,000 mg single ascending doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nacubactam 1,000 to 4,000 mg multiple ascending doses every 8 hours for up to 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nacubactam 2,000 mg plus meropenem 2,000 mg every 8 hours for 6 days after a 3-day lead-in period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35055783

Group type: EXPERIMENTAL
Intervention: Rhythmic initiation technique (RIT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Teaching correct breathing patterns
Number of subjects: 61
Study: 33887662

Group type: EXPERIMENTAL
Intervention: Real rTMS with physical therapy (PT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Real cTBS with physical therapy (PT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham cTBS with physical therapy (PT)
Number of subjects: 20
Study: 35973878

Group type: EXPERIMENTAL
Intervention: Illuminated musical mobile
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine sleep routines
Number of subjects: 124
Study: 33394989

Group type: EXPERIMENTAL
Intervention: L-T mode at output power of 60 W and 84 W
Number of subjects: 60

Group type: COMPARATOR
Intervention: L mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: L-T mode
Number of subjects: 60
Study: 35366419

Group type: EXPERIMENTAL
Intervention: AJM300 (960 mg) administered orally, three times daily for 8 weeks
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 33492021

Group type: EXPERIMENTAL
Intervention: Project Bridge (intensive case management intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 100
Study: 32315435

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Natural bovine bone mineral covered with resorbable native collagen membrane (BBM/CM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Freeze‐dried bone allograft covered with resorbable native collagen membrane (FDBA/CM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spontaneous healing (control)
Number of subjects: 40
Study: 34549819

Group type: EXPERIMENTAL
Intervention: Topical Antioxidants (AO) 2.0%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 32078089

Group type: EXPERIMENTAL
Intervention: Direct costs of mental health services and indirect costs from missed school and work.
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Higher anxiety and depression severity.
Number of subjects: 209
Study: 34809923

Group type: EXPERIMENTAL
Intervention: Proximal femoral nailing in the lateral position without a traction table (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Proximal femoral nailing in the supine position with a traction table (Group 2)
Number of subjects: 80
Study: 34463344

Group type: EXPERIMENTAL
Intervention: Integrated web-based intervention for PTSD symptoms and hazardous drinking (n = 81)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 162
Study: 33745292

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33352771

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet enriched in extra-virgin olive oil
Number of subjects: 6772

Group type: COMPARATOR
Intervention: Low-fat control intervention
Number of subjects: 6772

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 6772
Study: 36267895

Group type: EXPERIMENTAL
Intervention: Cisplatin-pemetrexed with intercalated erlotinib (CPE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Erlotinib monotherapy
Number of subjects: 22
Study: 34247613

Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence (stress UI)
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Urge urinary incontinence (urge UI)
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Urinary incontinence without stress or urge
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Barriers for healthcare-seeking for stress UI
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Barriers for healthcare-seeking for urge UI
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Barriers for healthcare-seeking for UI without stress or urge
Number of subjects: 4051

Group type: EXPERIMENTAL
Intervention: Association of educational level with barriers
Number of subjects: 4051
Study: 32301681

Group type: EXPERIMENTAL
Intervention: LIST
Number of subjects: 2

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 2
Study: 33707393

Group type: EXPERIMENTAL
Intervention: Integrated Amrita Meditation® technique (IAM®)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 35337223

Group type: EXPERIMENTAL
Intervention: rTMS combined with SLT
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham stimulation combined with SLT
Number of subjects: 67
Study: 34666379

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg twice daily) starting from 14 to 20 weeks' gestation until delivery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low dose aspirin (80 mg/day) and calcium (1 g/day)
Number of subjects: 80
Study: 35429974

Group type: EXPERIMENTAL
Intervention: Radiomic model based on intra-nodular and peri-nodular features
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Peri-nodular radiomic features
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Nomogram based on lobulation sign and radiomic features
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Clinical-semantic model
Number of subjects: 1018
Study: 32147827

Group type: EXPERIMENTAL
Intervention: Synbiotic tablets (T(+), T(-))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo tablets (C(+), C(-))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Synbiotic tablets (T(-))
Number of subjects: 80
Study: 36129998

Group type: EXPERIMENTAL
Intervention: Tofersen (100 mg, 8 doses over 24 weeks)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tofersen (100 mg, early-start cohort)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (delayed-start cohort)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tofersen
Number of subjects: 108
Study: 34127040

Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-synchronized nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 30
Study: 32614534

Group type: EXPERIMENTAL
Intervention: Ultra-light wheelchair
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lightweight wheelchair
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Standard wheelchair
Number of subjects: 18
Study: 35089507

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 160
Study: 33402094

Group type: EXPERIMENTAL
Intervention: Frailty Index (FI30) assessment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Age group 70 years and above
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Higher family income (Income>$473.3)
Number of subjects: 400
Study: 32965495

Group type: EXPERIMENTAL
Intervention: VP-102
Number of subjects: 528

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 528
Study: 35799272

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 34511464

Group type: EXPERIMENTAL
Intervention: Tivortin aspartate (40 ml daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (3% glucose solution, identical dosage and duration)
Number of subjects: 0
Study: 32725680

Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with metronidazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal group (no treatment)
Number of subjects: 120
Study: 35017255

Group type: EXPERIMENTAL
Intervention: Rapid Stratified Telehealth
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 33831037

Group type: EXPERIMENTAL
Intervention: Fatigue Group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study: 36441705

Group type: EXPERIMENTAL
Intervention: Nurse home visiting (NHV) - 25 nurse home visits (mean 23.2 home visits [SD 7.4, range 1-43] received) of 60-90 minutes, commencing antenatally and continuing until children's second birthdays.
Number of subjects: 722

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 722
Study: 34121413

Group type: EXPERIMENTAL
Intervention: MEDI6012 (intravenous doses of 24, 80, 240, and 800 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MEDI6012 (subcutaneous doses of 80 and 600 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MEDI6012 (intravenous doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MEDI6012 (subcutaneous doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MEDI6012 (all doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MEDI6012 (intravenous doses of 80, 240, and 800 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 32202313

Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based exercise program (24 weeks)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Non-theory-based exercise program
Number of subjects: 189
Study: 35900607

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg sc daily for 48 weeks)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Alendronate (70 mg oral weekly for 48 weeks)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 587

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 587
Study: 33245751

Group type: EXPERIMENTAL
Intervention: Post-induction patient-reported outcomes (PROs) of abdominal pain (AP) and stool frequency (SF)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Post-induction patient-reported outcomes (PROs) of stool frequency (SF)
Number of subjects: 220
Study: 32713213

Group type: EXPERIMENTAL
Intervention: Multicomponent incentive-based strategy
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Low-value noncash incentives linked to goal setting
Number of subjects: 512
Study: 32924586

Group type: EXPERIMENTAL
Intervention: IT + DL
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IT + IF
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IT
Number of subjects: 150

Group type: COMPARATOR
Intervention: ITsham
Number of subjects: 150

Group type: COMPARATOR
Intervention: NT
Number of subjects: 150